Stimwave and Nevro Reach Settlement In Patent Infringement Lawsuit

Proximie Raises $38m Series B Funding To Accelerate Its Expansion in U.S. and European Markets

F-Prime Capital led financing, joined by Questa Capital, Eight Roads, and Maverick Ventures

RhoVac Reports to Mount Sinai Hospital in New York Join Phase IIb Study in Prostate Cancer

The participation of Mount Sinai was directly caused by the FDA approval of RhoVac's Fast Track Designation.

For its spinal cord stimulation products only, Stimwave Technologies has agreed to a permanent injunction such that Stimwave’s spinal cord stimulation products will not deliver any therapy that includes pulse frequencies between 1,500 Hz and 100,000 Hz.

aul LaViolette, Stimwave’s chairman and interim CEO, said, “The new management team at Stimwave is pleased to put this litigation from past management behind us. We will continue to focus commercialization on the tiny form factor of our Freedom neurostimulators, which can be used throughout the body, eliminate the need for large internal batteries, and are fully MRI compatible.” He concluded, “Those attributes are the key to our products’ consistent double-digit annual growth and potential to disrupt both the spinal cord and peripheral nerve neuromodulation market.”



Related Articles